{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T12:39:13Z","timestamp":1791722353263,"version":"4.3.4"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,5,2]],"date-time":"2020-05-02T00:00:00Z","timestamp":1588377600000},"content-version":"vor","delay-in-days":397,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"crossref","award":["#001"],"award-info":[{"award-number":["#001"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Programa Nacional de Apoio ao Desenvolvimento da Metrologia, Qualidade e Tecnologia"},{"name":"Instituto Nacional de Metrologia, Qualidade e Tecnologia"},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado do Rio de Janeiro Carlos Chagas Filho"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Peptides"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.peptides.2019.04.004","type":"journal-article","created":{"date-parts":[[2019,4,14]],"date-time":"2019-04-14T09:42:31Z","timestamp":1555234951000},"page":"44-49","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["BZ043, a novel long-acting amylin analog, reduces gastric emptying, food intake, glycemia and insulin requirement in streptozotocin-induced diabetic rats"],"prefix":"10.1016","volume":"114","author":[{"given":"Caio Victor M.F.","family":"Nascimento","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celimar","family":"Sinezia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thayna","family":"Sisnande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu\u00eds Maur\u00edcio T.R.","family":"Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo G.S.","family":"Lacativa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.peptides.2019.04.004_bib0005","doi-asserted-by":"crossref","first-page":"179","DOI":"10.2337\/dc15-1585","article-title":"The time is right for a new classification system for diabetes: rationale and implications of the \u03b2-cell-centric classification schema","volume":"39","author":"Schwartz","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.peptides.2019.04.004_bib0010","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.2337\/dc18-S002","article-title":"2. Classification and diagnosis of diabetes: standards of medical care in diabetes\u20142018","volume":"41","author":"A.D. Association","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.peptides.2019.04.004_bib0015","series-title":"IDF Diabetes Atlas","author":"Federation","year":"2015"},{"key":"10.1016\/j.peptides.2019.04.004_bib0020","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/nrd.2015.36","article-title":"Pursuit of a perfect insulin","volume":"15","author":"Zaykov","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.peptides.2019.04.004_bib0025","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/j.1463-1326.2006.00686.x","article-title":"Insulin-associated weight gain in diabetes\u2013causes, effects and coping strategies","volume":"9","author":"Russell-Jones","year":"2007","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.peptides.2019.04.004_bib0030","doi-asserted-by":"crossref","first-page":"520","DOI":"10.2337\/diacare.7.6.520","article-title":"Normalization of insulin sensitivity in type I diabetic subjects by physical training during insulin pump therapy","volume":"7","author":"Yki-J\u00e4rvinen","year":"1984","journal-title":"Diabetes Care"},{"key":"10.1016\/j.peptides.2019.04.004_bib0035","doi-asserted-by":"crossref","first-page":"4492","DOI":"10.1111\/j.1582-4934.2008.00555.x","article-title":"Cell and molecular mechanisms of insulin-induced angiogenesis","volume":"13","author":"Liu","year":"2009","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.peptides.2019.04.004_bib0040","doi-asserted-by":"crossref","first-page":"8628","DOI":"10.1073\/pnas.84.23.8628","article-title":"Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients","volume":"84","author":"Cooper","year":"1987","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.peptides.2019.04.004_bib0045","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.1073\/pnas.84.11.3881","article-title":"Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islet cells","volume":"84","author":"Westermark","year":"1987","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.peptides.2019.04.004_bib0050","first-page":"151","article-title":"Inhibition of glucagon secretion","volume":"52","author":"Young","year":"2005","journal-title":"Adv. Pharmacol. San Diego Calif."},{"key":"10.1016\/j.peptides.2019.04.004_bib0055","first-page":"99","article-title":"Inhibition of gastric emptying","volume":"52","author":"Young","year":"2005","journal-title":"Adv. Pharmacol. San Diego Calif."},{"key":"10.1016\/j.peptides.2019.04.004_bib0060","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1590\/S0001-37652013005000011","article-title":"Amylin induces hypoglycemia in mice","volume":"85","author":"Guerreiro","year":"2013","journal-title":"An. Acad. Bras. Ci\u00eanc."},{"key":"10.1016\/j.peptides.2019.04.004_bib0065","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.neuropharm.2012.03.019","article-title":"Brainstem sensing of meal-related signals in energy homeostasis","volume":"63","author":"Young","year":"2012","journal-title":"Neuropharmacology"},{"issue":"Suppl","key":"10.1016\/j.peptides.2019.04.004_bib0070","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/jcb.240550003","article-title":"Amylin regulation of fuel metabolism","volume":"55","author":"Young","year":"1994","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.peptides.2019.04.004_bib0075","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1124\/pr.115.010629","article-title":"Amylin: pharmacology, physiology, and clinical potential","volume":"67","author":"Hay","year":"2015","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.peptides.2019.04.004_bib0080","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.2337\/diab.40.12.1615","article-title":"Decrease of stimulated amylin release precedes impairment of insulin secretion in type II diabetes","volume":"40","author":"Ludvik","year":"1991","journal-title":"Diabetes"},{"key":"10.1016\/j.peptides.2019.04.004_bib0085","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2337\/diaclin.20.3.137","article-title":"Amylin replacement with pramlintide in type 1 and type 2 diabetes: a physiological approach to overcome barriers with insulin therapy","volume":"20","author":"Buse","year":"2002","journal-title":"Clin. Diabetes"},{"key":"10.1016\/j.peptides.2019.04.004_bib0090","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1517\/14656566.2011.581663","article-title":"Pramlintide and the treatment of diabetes: a review of the data since its introduction","volume":"12","author":"Younk","year":"2011","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.peptides.2019.04.004_bib0095","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/dmrr.419","article-title":"Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study","volume":"20","author":"Maggs","year":"2004","journal-title":"Diabetes Metab. Res. Rev."},{"key":"10.1016\/j.peptides.2019.04.004_bib0100","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1111\/dom.12504","article-title":"Fixed ratio dosing of pramlintide with regular insulin before a standard meal in patients with type 1 diabetes","volume":"17","author":"Riddle","year":"2015","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.peptides.2019.04.004_bib0105","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/oby.2004.76","article-title":"Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients","volume":"12","author":"Hollander","year":"2004","journal-title":"Obes. Res."},{"key":"10.1016\/j.peptides.2019.04.004_bib0110","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1210\/jc.2006-2003","article-title":"Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study","volume":"92","author":"Aronne","year":"2007","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2019.04.004_bib0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bpc.2016.09.007","article-title":"Amyloidogenesis of the amylin analog pramlintide","volume":"219","author":"da Silva","year":"2016","journal-title":"Biophys. Chem."},{"key":"10.1016\/j.peptides.2019.04.004_bib0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2018.06.039","article-title":"Physico-chemical properties of co-formulated fast-acting insulin with pramlintide","author":"da Silva","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.peptides.2019.04.004_bib0125","doi-asserted-by":"crossref","DOI":"10.2337\/db18-210-OR","article-title":"Insulin-plus-pramlintide artificial pancreas in type 1 diabetes\u2014randomized controlled trial","volume":"67","author":"Haidar","year":"2018","journal-title":"Diabetes"},{"key":"10.1016\/j.peptides.2019.04.004_bib0130","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1093\/ajhp\/62.8.816","article-title":"Properties of pramlintide and insulin upon mixing","volume":"62","author":"Weyer","year":"2005","journal-title":"Am. J. Health-Syst. Pharm. AJHP"},{"key":"10.1016\/j.peptides.2019.04.004_bib0135","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/bph.13723","article-title":"A novel dual amylin and calcitonin receptor agonist, KBP-089, induces weight loss through a reduction in fat, but not lean mass, while improving food preference","volume":"174","author":"Gydesen","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.peptides.2019.04.004_bib0140","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1124\/jpet.117.241281","article-title":"The dual amylin- and calcitonin-receptor agonist KBP-042 works as adjunct to metformin on fasting hyperglycemia and hba1c in a rat model of type 2 diabetes","volume":"362","author":"Hjuler","year":"2017","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.peptides.2019.04.004_bib0145","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s10928-017-9557-6","article-title":"Modeling energy intake and body weight effects of a long-acting amylin analog","volume":"45","author":"Brings","year":"2018","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.peptides.2019.04.004_bib0150","doi-asserted-by":"crossref","first-page":"E24","DOI":"10.1152\/ajpendo.00121.2014","article-title":"A novel oral dual amylin and calcitonin receptor agonist (KBP-042) exerts antiobesity and antidiabetic effects in rats","volume":"307","author":"Andreassen","year":"2014","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.peptides.2019.04.004_bib0155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0138803","article-title":"Monoconjugation of human amylin with methylpolyethyleneglycol","volume":"10","author":"Sisnande","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.peptides.2019.04.004_bib0160","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.peptides.2015.04.010","article-title":"Neuromedin U inhibits food intake partly by inhibiting gastric emptying","volume":"69","author":"Dalb\u00f8ge","year":"2015","journal-title":"Peptides"},{"key":"10.1016\/j.peptides.2019.04.004_bib0165","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/j.1463-1326.2012.01569.x","article-title":"Empagliflozin, a novel potent and selective SGLT-2 inhibitor, improves glycaemic control alone and in combination with insulin in streptozotocin-induced diabetic rats, a model of type 1 diabetes mellitus","volume":"14","author":"Luippold","year":"2012","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.peptides.2019.04.004_bib0170","series-title":"Amylin, Volume 52: Physiology and Pharmacology","author":"Young","year":"2005"},{"key":"10.1016\/j.peptides.2019.04.004_bib0175","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/(SICI)1098-2299(199604)37:4<231::AID-DDR5>3.0.CO;2-M","article-title":"Preclinical pharmacology of pramlintide in the rat: comparisons with human and rat amylin","volume":"37","author":"Young","year":"1996","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.peptides.2019.04.004_bib0180","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1007\/s11892-006-0004-0","article-title":"Pramlintide: a new tool in diabetes management","volume":"6","author":"Want","year":"2006","journal-title":"Curr. Diab. Rep."},{"key":"10.1016\/j.peptides.2019.04.004_bib0185","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1111\/j.1463-1326.2010.01201.x","article-title":"Safety of pramlintide added to mealtime insulin in patients with type 1 or type 2 diabetes: a large observational study","volume":"12","author":"Pencek","year":"2010","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.peptides.2019.04.004_bib0190","doi-asserted-by":"crossref","DOI":"10.2337\/db18-349-OR","article-title":"BioChaperone technology enables the development of pramlintide-prandial insulin combinations","volume":"67","author":"Meiffren","year":"2018","journal-title":"Diabetes"},{"key":"10.1016\/j.peptides.2019.04.004_bib0195","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1208\/s12249-013-9987-4","article-title":"Preparation and characterization of PEGylated amylin","volume":"14","author":"Guerreiro","year":"2013","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.peptides.2019.04.004_bib0200","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.2174\/09298665113209990067","article-title":"Amylin conjugation with methoxyl polyethyleneglycol","volume":"20","author":"Guterres","year":"2013","journal-title":"Protein Pept. Lett."},{"key":"10.1016\/j.peptides.2019.04.004_bib0205","doi-asserted-by":"crossref","DOI":"10.1080\/10837450.2019.1621896","article-title":"Physico-chemical stability of co-formulation of PEGylated human amylin with insulin","author":"Sinezia","year":"2019","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.peptides.2019.04.004_bib0210","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1111\/bph.13496","article-title":"Amylin structure\u2013function relationships and receptor pharmacology: implications for amylin mimetic drug development","volume":"173","author":"Bower","year":"2016","journal-title":"Br. J. Pharmacol."}],"container-title":["Peptides"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019697811930035X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019697811930035X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T09:24:01Z","timestamp":1759310641000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S019697811930035X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":42,"alternative-id":["S019697811930035X"],"URL":"https:\/\/doi.org\/10.1016\/j.peptides.2019.04.004","relation":{},"ISSN":["0196-9781"],"issn-type":[{"value":"0196-9781","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"BZ043, a novel long-acting amylin analog, reduces gastric emptying, food intake, glycemia and insulin requirement in streptozotocin-induced diabetic rats","name":"articletitle","label":"Article Title"},{"value":"Peptides","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.peptides.2019.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}